Egetis reports tiratricol lowers FT4 by 37% in retrospective RTH — beta study

Egetis Therapeutics announced publication of a retrospective study supporting tiratricol’s potential in resistance to thyroid hormone beta. The study included 28 patients, with median treatment lasting 50 months; results showed lower thyroid hormone levels and reduced heart rate. Findings support existing European treatment recommendations and could underpin prospective clinical trials. Development planning remains ongoing, with preparations for regulatory discussions underway. Tiratricol is not licensed for RTH-beta, which has no approved therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein. (C)